Dolcyl 2 mg 30 tablets

Dolcyl

Compound:

Each tablet contains:

Glimepiride 2 mg

Properties:

Hypoglycemic drug for oral administration – a third generation sulfonylurea derivative.

Glimepiride acts primarily by stimulating the secretion and release of insulin from pancreatic β-cells (pancreatic action). As with other sulfonylurea derivatives, this effect is based on an increase in the response of pancreatic β-cells to physiological stimulation with glucose, while the amount of secreted insulin is much less than with the action of traditional drugs – sulfonylurea derivatives. The least stimulating effect of glimepiride on insulin secretion also provides a lower risk of hypoglycemia. In addition to this, glimepiride has an extrapancreatic effect – the ability to improve the sensitivity of peripheral tissues (muscle, fat) to the action of its own insulin, reduce the absorption of insulin by the liver; inhibits the production of glucose in the liver. Glimepiride selectively inhibits cyclooxygenase and reduces the conversion of arachidonic acid to thromboxane A2, which promotes platelet aggregation, thus exerting an antithrombotic effect.

Glimepiride contributes to the normalization of lipid levels, reduces the level of malonic aldehyde in the blood, which leads to a significant decrease in lipid peroxidation, this contributes to the antiatherogenic effect of the drug.

Indications:

Treatment of type 2 diabetes mellitus with the ineffectiveness of a previously prescribed diet and exercise.

If monotherapy with glimepiride is ineffective, it can be used in combination therapy with metformin or insulin.

Dosage and administration:

The average initial dosage is 1-2 mg once a day during breakfast.

The maximum starting dosage is 2 mg.

Contraindications:

-diabetes mellitus type 1;

– diabetic ketoacidosis,

– diabetic precoma and coma;

– conditions accompanied by impaired absorption of food and the development of hypoglycemia (infectious diseases);

– leukopenia;

– severe liver dysfunction;

– severe renal dysfunction (including patients on hemodialysis);

– lactose intolerance, lactase deficiency, glucose-galactose malabsorption;

-pregnancy;

-lactation;

– hypersensitivity to glimepiride or to any inactive component of the drug, to other sulfonylurea derivatives or to sulfanilamide drugs (risk of developing hypersensitivity reactions).

Precautionary measures:

Glimepiride should be taken at the recommended doses and times. Errors in the use of the drug, such as skipping a dose, can never be eliminated by a subsequent dose of a higher dose. The doctor and the patient should discuss in advance the measures to be taken in case of such errors (for example, skipping a drug or meal) or in situations where it is impossible to take the next dose of the drug at the set time. The patient should immediately inform the doctor in case of taking too high a dose of the drug.

Side effects:

From the side of metabolism: in rare cases, the development of hypoglycemic reactions is possible.

On the part of the organ of vision: during treatment (especially at its beginning), transient visual impairment may occur due to changes in the concentration of glucose in the blood.

From the digestive system: sometimes there may be nausea, vomiting, a feeling of heaviness or discomfort in the epigastrium.

Storage method:

Store at a temperature not exceeding 25 degrees.

Package:

The cardboard box contains 3 blisters of 10 tablets, paper instructions.